Screening and prostate-cancer mortality in a randomized European study.

Screening and prostate-cancer mortality in a randomized European study.

BACKGROUND: The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer. METHODS: We identified 182,000 men between the ages of 50 and 74 years thr...

Full description

Bibliographic Details
Main Authors:	Schröder, F, Hugosson, J, Roobol, M, Tammela, T, Ciatto, S, Nelen, V, Kwiatkowski, M, Lujan, M, Lilja, H, Zappa, M, Denis, L, Recker, F, Berenguer, A, Määttänen, L, Bangma, C, Aus, G, Villers, A, Rebillard, X, van der Kwast, T, Blijenberg, BG, Moss, S, de Koning, H, Auvinen, A
Format:	Journal article
Language:	English
Published:	2009

Similar Items

Prostate-cancer mortality at 11 years of follow-up.
by: Schröder, F, et al.
Published: (2012)

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
by: Roobol, M, et al.
Published: (2009)

Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands.
by: Auvinen, A, et al.
Published: (2009)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
by: Bangma, C, et al.
Published: (2010)

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
by: de Koning, H, et al.
Published: (2002)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
by: Vickers, A, et al.
Published: (2010)

Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees.
by: Bergdahl, A, et al.
Published: (2009)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
by: Vickers, A, et al.
Published: (2009)

Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA committee.
by: Blijenberg, BG, et al.
Published: (2003)

Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.
by: Aus, G, et al.
Published: (2007)

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
by: Hugosson, J, et al.
Published: (2004)

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
by: Carlsson, S, et al.
Published: (2012)

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
by: Aus, G, et al.
Published: (2005)

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
by: Aus, G, et al.
Published: (2003)

Erratum: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section (International Journal of Cancer (2007) 120, (170-174))
by: Khatami, A, et al.
Published: (2007)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
by: Aus, G, et al.
Published: (2004)

Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection.
by: Zackrisson, B, et al.
Published: (2003)

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
by: Hugosson, J, et al.
Published: (2003)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
by: Zackrisson, B, et al.
Published: (2003)

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
by: Zackrisson, B, et al.
Published: (2004)

Screening for prostate cancer: early detection or overdetection?
by: Vickers, A, et al.
Published: (2012)

Prognostic value of serum markers for prostate cancer.
by: Stenman, U, et al.
Published: (2005)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
by: Vickers, A, et al.
Published: (2010)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
by: Hugosson, J, et al.
Published: (2003)

Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.
by: Hugosson, J, et al.
Published: (2000)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.
by: Roobol, M, et al.
Published: (2012)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
by: Vickers, A, et al.
Published: (2010)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
by: Vickers, A, et al.
Published: (2008)

Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
by: Ankerst, D, et al.
Published: (2014)

Mortality results from the Goteborg randomised population-based prostate-cancer screening trial.
by: Hugosson, J, et al.
Published: (2010)

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
by: Ankerst, D, et al.
Published: (2012)

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
by: Vickers, A, et al.
Published: (2010)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
by: Gupta, A, et al.
Published: (2010)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
by: Vickers, A, et al.
Published: (2010)

Screening for prostate cancer.
by: Carlsson, S, et al.
Published: (2012)

Screening for prostate cancer: To the editor
by: Carlsson, S, et al.
Published: (2012)

THE P-MARK BIOBANK: A EUROPEAN MULTICENTER BIOREPOSITORY FOR PROSTATE CANCER RESEARCH
by: Marsden, G, et al.
Published: (2009)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
by: Benchikh, A, et al.
Published: (2010)

On the application of solar radiation momentum transfer to space vehicle propulsion
by: Villers, Philippe
Published: (2005)

Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.
by: Hugosson, J, et al.
Published: (2001)